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Abstract
Background: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis causes end-stage renal failure in up
to a third of cases even with treatment. The disease recurs occasionally after kidney transplantation, but new onset
of ANCA-associated vasculitis after transplantation is highly unusual. The use of rituximab or plasmapheresis for de
novo disease after transplantation has not previously been reported.
Case presentation: Routine post-transplant follow-up for a 66-year old asymptomatic woman revealed a rise in
creatinine from 1.8 to 2.6 mg/dl and increased proteinuria. She had received a cadaveric kidney transplant
20 months previously for end-stage autosomal dominant polycystic kidney disease. Renal allograft biopsy
unexpectedly demonstrated pauci-immune glomerulonephritis with extracapillary proliferation and interstitial
inflammation. Concurrent serum tested strongly positive for ANCA specific to proteinase 3 (PR3), but stored
pre- and post-transplantation serum samples tested negative. These findings established a diagnosis of de
novo ANCA-associated vasculitis in the renal allograft.
We started treatment with high-dose corticosteroid and rituximab. Despite this, serum creatinine continued to rise and
glomerulonephritis remained active in a repeat biopsy. Escalation of the treatment with seven sessions of plasmapheresis
led to a temporary improvement in creatinine. No further features of vasculitis emerged and PR3-ANCA titres declined.
However, multiple infections complicated the recovery period and were associated with progressive loss of renal
transplant function. Four months after the index presentation, transplant function became insufficient and dialysis
was restarted.
Conclusions: De novo ANCA-associated vasculitis after renal transplantation is exceptionally rare. It poses a
significant risk to graft survival even in the context of intensified immunosuppression. Management relies on
clinical evidence from populations with native renal function, yet post-transplant patients may be at increased
risk of treatment-related adverse events. Precautions against these risks are crucial in the delivery of care.
Keywords: ANCA, Vasculitis, Kidney transplantation, de novo, Rituximab, Case report
* Correspondence: Ulf.Schoenermarck@med.uni-muenchen.de
1Nephrology Division, Medizinische Klinik und Poliklinik IV, Klinikum der
Universität München - Campus Großhadern, Munich, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sagmeister et al. BMC Nephrology          (2018) 19:270 
https://doi.org/10.1186/s12882-018-1086-z
Background
Anti-neutrophil cytoplasmic antibody-associated vascu-
litis (AAV) is a rare autoimmune disorder leading to
necrotising inflammation of small blood vessels and tis-
sue damage [1]. It commonly affects the kidneys causing
end-stage renal failure (ESRF) in 20–40% of cases [2].
Advancement in the management of AAV has been
achieved through randomised controlled trials in popula-
tions with native renal function [3]. These have validated
cyclophosphamide, and more recently rituximab, in com-
bination with corticosteroids as effective treatments.
Less is known about AAV affecting renal transplants.
Relapse of AAV in kidney transplants has been described
for 42 cases as part of multiple small case series, not
counting individual case reports [4]. Graft loss resulted
in over a third despite intensified immunosuppression.
Only two cases of de novo AAV after kidney transplant-
ation have been described [5, 6]. Both occurred more
than 10 years after transplantation, were treated with
corticosteroid or corticosteroid plus cyclophosphamide
and resulted in significant deterioration of graft function.
We report a case of de novo AAV within 2 years of
transplantation whose treatment included rituximab and
plasmapheresis. We describe the presentation and course
of AAV in this unusual context and discuss the evidence
basis that informed our management.
Case presentation
A 66-year old woman of Turkish descent attended our
clinic in January 2015. She was asymptomatic at a rou-
tine follow-up 20 months after kidney transplantation
and had an unremarkable physical examination. Of note,
her creatinine had risen from 1.8 to 2.6 mg/dl since
April 2014 and the urinary protein-creatinine-ratio had
increased from 200 to 440 mg/g. Microhaematuria was
absent at first, but became evident on repeat testing
within 1 week (20 red cells per high-power field, no red
cell casts).
Her background medical history consisted of coronary
artery disease, hypertension, asymptomatic sinusitis and
obesity. She had no known history of connective tissue
or autoimmune disease. She had reached ESRF second-
ary to autosomal dominant polycystic kidney disease at
the age of 58 years. After 7 years of haemodialysis, she
received a deceased-donor kidney transplant without in-
duction immunosuppression in May 2013 (baseline
characteristics and human leucocyte antigen (HLA)
genotyping of recipient and donor are shown in Table 1).
An episode of asymptomatic cytomegalovirus (CMV) re-
activation (1160 CMV copies / ml) 8 months after trans-
plantation responded to valganciclovir and reduction of
mycophenolate dose. At the index presentation, medica-
tions had been unchanged for more than 3 months.
These were prednisolone 5 mg OD, cyclosporine A
50 mg BD, pantoprazole 20 mg OD, metoprolol
47.5 mg BD, doxazosin 4 mg BD, aspirin 100 mg OD,
simvastatin 20 mg OD, allopurinol 150 mg OD and
calcitriol 0.25 μg OD.
A biopsy of the kidney transplant in response to the
unexplained rise in creatinine showed eleven glomeruli,
three of which were globally sclerotic. Unexpectedly,
three of the remaining glomeruli demonstrated extraca-
pillary proliferative changes, with crescent formation
and necrosis in two (Fig. 1). Interstitial inflammation
with eosinophilic cells and borderline changes suspicious
for acute cellular rejection (Banff 3) were also seen. The
lack of deposition of complement or immunoglobulins
indicated a histological diagnosis of pauci-immune cres-
centic glomerulonephritis.
Autoimmune serology tested strongly positive for
anti-neutrophil cytoplasmic antibodies (ANCA) with a
typical cytoplasmic immunofluorescence pattern and speci-
ficity to proteinase 3 (PR3) (Euroimmun, Germany). ANCA
specific to myeloperoxidase (MPO), anti-glomerular base-
ment membrane antibodies, anti-nuclear antibodies and
cryoglobulins were negative; complement and alpha-
1-antitrypsin levels were normal. Donor-specific HLA anti-
bodies were tested at time of biopsy and were negative.
Retrospective analyses of frozen serum samples from
49 days prior and 36, 63, 96, 226 and 335 days
post-transplantation were all negative for PR3-ANCA
or MPO-ANCA. Lung involvement could be excluded
with CT scan. A clinical review for vasculitis-typical
features revealed that nasal crusting and bloody nasal
discharge, the only extrarenal manifestations, had de-
veloped several months before the transplant biopsy.
All of these findings supported the diagnosis of AAV and
its specific subtype granulomatosis with polyangiitis.
We commenced treatment with intravenous prednisol-
one 250 mg for 3 days followed by rituximab 1 g and
oral prednisolone 50 mg/day. Despite this, serum
Table 1 Transplant donor and recipient characteristics,
including genetic HLA types
Donor Recipient
Age (years) 73 65
Gender male female
CMV serostatus positive positive
MHC class I A*02, 68 A*01, 32
B*51,53 B*35, −
C*04,14 C*04, −
MHC class IIa DRB1*13, 08 DRB1*11, 14
DQB1*06, 04 DQB1*03, 05
Panel reactive antibody 0%
Cold ischaemia time (hours) 10,5
aHLA-DP was not tested as part of the transplant matching process
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creatinine rose to 4.1 mg/dl over the next 2 weeks,
prompting a second transplant biopsy 19 days after the
first. The repeat biopsy contained 14 glomeruli, four of
which were globally sclerotic. Three of the remaining
glomeruli showed extracapillary proliferative changes
and one of these exhibited necrosis. Minor features of is-
chaemia and mild interstitial inflammation were present,
but no signs of rejection. Immunohistochemistry and elec-
tron microscopy remained consistent with pauci-immune
glomerulonephritis.
In view of the refractory disease course, we added
seven sessions of plasma exchange. This was followed by
a second administration of rituximab 1 g, a tapering
course of oral prednisolone and antibiotic prophylaxis
with co-trimoxazole. After 2 weeks, serum creatinine de-
clined to 2.6 mg/dl, suggesting a partial recovery of renal
graft function. The patient’s clinical course is sum-
marised in Fig. 2.
A series of complications ensued. The patient devel-
oped corticosteroid-related diabetes mellitus, pneumonia
with neutropenia and CMV reactivation in serum (586
copies / ml), requiring antimicrobial and antiviral ther-
apy. Interventional occlusion of an arteriovenous fistula
that had emerged after the first biopsy did not avert the
rising trend in creatinine. A second infection episode oc-
curred, fluid retention became problematic and creatinine
rose to 7 mg/dl. Regular haemodialysis was recommenced
from May 2015 onwards, 24 months after transplantation
and 4 months after the initial presentation with rising cre-
atinine and proteinuria. Transplant related immunosup-
pressive therapy with cyclosporine and mycophenolate
was tapered and consecutively stopped while low-dose
therapy with prednisolone for treatment of AAV was con-
tinued. The transplanted kidney was resected in Septem-
ber 2015 due to the new development of donor-specific
HLA antibodies (anti-HLA-A2) and persistent haema-
turia. Histological examination found chronic and active
antibody-mediated and cellular rejection, but no extraca-
pillary proliferation. Rituximab was continued for main-
tenance therapy. PR3-ANCA remained positive, but
declined steadily. There has been no further clinical vascu-
litis activity during follow-up for 2 years.
Discussion and conclusions
We present a case of de novo AAV 20 months after kid-
ney transplantation. The diagnosis of AAV is based on
histological presence of pauci-immune crescentic glom-
erulonephritis and positive PR3-ANCA. No prior history
of vasculitis symptoms and ANCA-negative tests on
stored serum samples going back to the pre-transplant
and immunosuppression-naïve phase support a de novo
manifestation of the disease.
Our literature search found only two distinct cases of
de novo AAV after kidney transplantation (13 and
14 years post-transplantation) [5, 6]. We suggest three
explanations for the scarcity of this phenomenon. Firstly,
it represents a rare disease in a small population at risk
(incidence rate of AAV in the general population: 13 to
20 per million; prevalence of patients with kidney trans-
plant in the UK: 462 per million) [7, 8]. Secondly, verifi-
cation of AAV as de novo after transplantation is not
always feasible. Thirdly, maintenance immunosuppres-
sion for prevention of transplant rejection is likely to
protect against development of AAV, given that the re-
lapse rate of AAV after renal transplantation is lower
than in patients with native renal function or on dialysis
[9]. Anti-rejection therapies downregulate T cells, which
have been implicated in the pathophysiology of AAV.
Immunosuppression in transplant patients is however
best understood as threshold modulation for adaptive
Fig. 1 Light microscopy findings for the first biopsy of the transplant
kidney. a Renal cortex with one normal glomerulus (top left corner)
and one glomerulus exhibiting extracapillary proliferation, loss of
integrity in Bowman’s capsule, fibrin deposition and focal necrosis
(arrow; haematoxylin and eosin staining, original magnification × 100).
b Detailed view of pathological glomerulus from above. There is also
an interstitial inflammatory infiltrate including multiple eosinophilic
granulocytes (arrowheads; original magnificent × 400)
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immune responses rather than their complete suppres-
sion, as illustrated by the occurrence of de novo
donor-specific antibodies or immunological responses to
vaccination [10, 11]. For these reasons, de novo AAV
will remain exceptionally rare in kidney transplant pa-
tients, but close monitoring practises for this group will
lead to detection of further cases.
The aetiology of AAV is not fully understood, but in-
volves genetic as well as environmental factors. Genes
from the major histocompatibility complex and other
loci influence disease susceptibility and the clinical
course [12, 13]. The HLA type DRB1*14, present in our
patient, is linked with a moderate predisposition to AAV
(odds ratio 1.91). Environmental risk factors may pre-
cipitate AAV, but antecedent infection, pertinent medi-
cations, silica exposure or heavy metal exposure were
not present as far as we can tell [8, 14]. Reports about the
deceased donor and the contra-lateral kidney recipient
were unremarkable for vasculitis or autoimmune diseases.
Our patient’s immunosuppression had been reduced in re-
sponse to CMV reactivation and this may have diminished
protection against AAV development. While ANCA are
believed to emerge from pro-inflammatory milieus within
tissues, we cannot tell if the interstitial inflammation and
mild tubulitis seen in the initial biopsy are cause or effect
in relation to AAV. To our knowledge, there were no in-
fections, rheumatologic symptoms or new medications at
the time that might point to an alternative cause for inter-
stitial inflammation. As with nearly all cases of AAV, an
explanation of the aetiology remains elusive.
For the first time, we report the use of rituximab for
de novo AAV after kidney transplantation. Clinical
Fig. 2 Overview of the patient’s clinical course and management
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evidence on the management of AAV in the post-trans-
plant setting is scarce. In the two reported cases of de
novo AAV, treatment with steroid and cyclophospha-
mide or steroid alone led to graft loss after 5 years or
significantly impaired graft function at 6 months re-
spectively [5, 6]. There are several retrospective case
series on the management of disease relapses after trans-
plantation, the largest comprising 13 patients [4, 15].
While older reports more commonly quote the use of
cyclophosphamide, we found thirteen cases that were
treated with rituximab [15–21]. Twelve of these res-
ponded to rituximab-based therapy, although publica-
tion bias may exaggerate this apparent efficacy. The
strongest rationale for the use of rituximab comes from
two randomised controlled trials in populations with na-
tive renal function which show equivalent efficacy and
safety of rituximab compared to cyclophosphamide
[22, 23]. The rare nature of post-transplant AAV
means that clinicians have to rely on clinical evidence
from related contexts like these trials to inform their
management. We argue that rituximab can be consid-
ered as a therapeutic option. Even though kidney func-
tion could not be preserved declining PR3-ANCA
levels and the lack of further vasculitic organ manifes-
tations during follow-up demonstrate at least partial
effectiveness in our case.
The initial lack of response to treatment brought add-
itional complexity to our case. The rate of refractory
AAV has been 2% to 5% in recent clinical trials for pop-
ulations with native renal function [24]. We opted to es-
calate treatment with plasmapheresis. Although this
improves renal survival without impact on overall sur-
vival for patients with severe renal impairment at pres-
entation according to previous trial evidence [25], the
final results of a recent large international trial are
awaited to clarify the role of plasmapheresis as adjunct-
ive therapy in first-line management (PEXIVAS; clinical-
trials.gov ID: NCT00987389). There is currently no
consensus for the management of treatment-resistant
AAV and alternative strategies are discussed in recent
reviews [24, 26]. Further uncertainty concerns the main-
tenance immunosuppression in transplant patients with
AAV. Commonly used anti-rejection agents are probably
equivalent in prophylaxis of AAV relapses, but their
handling during or after AAV (re-)induction therapy has
received little consideration [9]. We re-introduced my-
cophenolate at a low dose, acknowledging also signs of
mild cellular rejection in the first biopsy. These chal-
lenges from our case are infrequent but can be serious
problems in AAV. Addressing them will require further
research including high-quality retrospective studies.
Despite increased immunosuppressive therapy fur-
ther decline of kidney function occurred as a conse-
quence of vasculitic damage. However, the eventual
loss of transplant function in our patient was partly
due to treatment-related adverse events limiting fur-
ther intensification of therapy. Their influence, par-
ticularly with respect to infections, on morbidity and
mortality in AAV is well characterised [27, 28]. As ob-
served in our case, the commonest type of infection is
pneumonia, the risk is highest during the most intense
phase of immunosuppression and infections are associ-
ated with leukopenia and renal impairment. Adverse
event rates specifically for AAV therapy after transplant-
ation are not available. A higher burden of co-morbidities,
lower renal function, pre-existing immunosuppression
and sensitisation of the immune system to graft rejection
may predispose this cohort to complications. Rituximab
and plasmapheresis have an expanding range of applica-
tions in the post-transplant setting and respective data on
their safety profiles is emerging [29, 30]. Bearing in mind
the devastating prognosis of untreated AAV, successful
management depends on the right level of immunosup-
pression that will control vasculitis activity and limit
adverse events. Achieving this balance is a key research
area for AAV currently and is especially challenging for
post-transplant patients. Close monitoring and careful
precautions are therefore crucial to avert poor out-
comes related to treatment.
De novo AAV after renal transplantation is exception-
ally rare. There is insufficient data to elucidate possible
differences in pathophysiology or prognosis of AAV in
transplant kidneys compared to native kidneys. Active
AAV in the renal allograft carries a significant risk of
graft loss even in the context of intensified immunosup-
pression. Current management is informed by evidence
from randomised controlled trials on patients with na-
tive renal function and case series on patients with
AAV relapse after renal transplantation. Despite the
availability of rituximab as a novel therapeutic option,
treatment-related adverse events remain problematic.
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